Author:
Matthews Gail,Jacoby Simone,Borok Margaret,Eriobu Nnakelu,Kaplan Richard,Kumarasamy Nagalingeswaran,Bennet Jaclyn Ann,Avihingsanon Anchalee,Chetchotisakd Ploenchan,Wagner Cardoso Sandra,Azwa Iskandar,Losso Marcelo,Brown Dannae,Arlinda Dona,Hutchinson Jolie,Kelleher Anthony,Cisse Mohamed,Dao Sounkalo,Polizzotto Mark,Emery Sean,Law Matthew,Papot Emmanuelle,Karyana Muhammad,Lupo Sergio,Solari Ana Melisa,Grinsztejn Beatriz,Wolff Marcello,Andrade-Villanueva Jaime,Mosqueda Gómez Juan Luis,Chow Ting Soo,Mohapi Lerato,Yunihastuti Evy,Hadi Usman,Katu Sudirman,Subronto Yanri Wijayanti,Lane H. Clifford,Perelis Leonardo
Reference21 articles.
1. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations,2022
2. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV,2023
3. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial;Aboud;Lancet Infect Dis,2019
4. Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV;Paton;N Engl J Med,2021
5. Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT;Papot;HIV Res Clin Pract,2022